Plasma DNA methylation detection for early screening, diagnosis, and monitoring of esophageal adenocarcinoma and squamous cell carcinoma

Figure 4 Receiver operating characteristic curve analysis of SHOX2, RNF180, SEPTIN9, and EPO methylation biomarkers. A-D: Receiver operating characteristic (ROC) curves of methylation for squamous cell carcinoma. Area under the curve (AUC)-SHOX2 = 0.639 (95%CI: 0.575–0.703), AUC-SEPTIN9 = 0.731 (95%CI: 0.673–0.789), AUC-EPO = 0.765 (95%CI: 0.710–0.820), and AUC-RNF180 = 0.559 (95%CI: 0.491–0.626); E-H: ROC curve analysis of methylation for adenocarcinoma. AUC-SHOX2 = 0.601 (95%CI: 0.484–0.719), AUC-SEPTIN9 = 0.626 (95%CI: 0.504–0.749), AUC-EPO = 0.691 (95%CI: 0.577–0.805), and AUC-RNF180 = 0.697 (95%CI: 0.582–0.813). ROC: Receiver operating characteristic.